Navegando por Palavras-chave "siRNA"

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    A Interleucina 1-beta mostra uma ação protetora na fase aguda do modelo de epilepsia induzido pela pilocarpina
    (Liga Brasileira de Epilepsia (LBE), 2010-09-01) Pascoal, Vinícius d b; Marchesini, Rafael Breglio; Matos, Anabela hb; Conte, Fábio Frangiotti; Pereira, Tiago Campos; Gilioli, Rovilson; Malheiros, Jackeline Moraes [UNIFESP]; Polli, Roberson Saraiva [UNIFESP]; Buzzá, Hilde H; Tannús, Alberto; Covolan, Luciene [UNIFESP]; Cavalheiro, Esper Abrão [UNIFESP]; Velloso, Lício Augusto; Cendes, Fernando; Lopes-Cendes, Íscia; Universidade Estadual de Campinas (UNICAMP); Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)
    INTRODUCTION: There is contradictory information regarding the of effects il1β and il1rn in epilepsy. We aimed to evaluate the effect of silencing both genes in the acute phase of the pilocarpine-induced epilepsy model. METHODS: We used RNA interference in order to achieve gene silencing. RESULTS: We obtained significant gene silencing in the central nervous system. In addition, we observed phenotypic effects including differences in mortality rates of animals 5 days after pilocarpine injections. CONCLUSION: Our results indicate that il1β seems to have a protective effect in the acute phase of the pilocarpine-induced epilepsy model.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis
    (Expert Reviews, 2008-07-01) Okamoto, Oswaldo Keith [UNIFESP]; Perez, Jose Fernando [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    This review discusses some of the impacts that biotechnology, genomics and nanotechnology convergence should have on future cancer management, in particular, the development of innovative diagnostic and therapeutic approaches based on monoclonal antibodies (mAbs) and cancer stem cells. Emergent therapeutic strategies in cancer have been focusing on the use of mAbs to stimulate an immune response against tumors, to block signaling pathways, or to refine delivery of cytotoxic agents. Now that cancer stem cells are being identified and characterized in different tumor types, their relevance to cancer physiopathology is becoming evident, making them natural targets for mAb development. Cancer stem cells are postulated to be responsible for tumor development, metastasis and relapse after conventional therapies. Therefore, mAbs targeting specific antigens and related pathways altered in cancer stem cells should facilitate earlier diagnosis through molecular imaging techniques and more efficient destruction of tumor initiating cells, thus improving clinical outcome.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    The Underexploited Role of Non-Coding RNAs in Lysosomal Storage Diseases
    (Frontiers Media Sa, 2016) Queiroz, Matheus Trovao de [UNIFESP]; Pereira, Vanessa Goncalves [UNIFESP]; Nascimento, Cinthia Castro do [UNIFESP]; D'Almeida, Vania [UNIFESP]
    Non-coding RNAs (ncRNAs) are a functional class of RNA involved in the regulation of several cellular processes which may modulate disease onset, progression, and prognosis. Lysosomal storage diseases (LSD) are a group of rare disorders caused by mutations of genes encoding specific hydrolases or non-enzymatic proteins, characterized by a wide spectrum of manifestations. The alteration of ncRNA levels is well established in several human diseases such as cancer and auto-immune disorders